Why insider trading matters?

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

- Peter Lynch
Gritstone Oncology, Inc. (GRTS)
Sector: Healthcare; Industry: Biotechnology

Gritstone Oncology, Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-05-27 Rousseau Raphael nan Sell 2,900 $9.00 $26,112 Yes
2021-01-20 Rousseau Raphael nan Sell 30,000 $20.04 $601,269 Yes
2021-01-19 Yelensky Roman nan Sell 10,000 $22.10 $221,029 No
2020-12-30 Woiwode Thomas Director Buy 1,347,709 $3.71 $5,000,000 No
2019-08-21 Rousseau Raphael See Remarks Sell 10,000 $10.76 $107,631 Yes
2018-09-28 Simon Nicholas 10%-Owner, Director Buy 333,333 $15.00 $4,999,995 Yes
2018-09-28 Clarus Lifesciences III, L.P. 10%-Owner Buy 333,333 $15.00 $4,999,995 Yes

Insider Smart

Altimmune, Inc. (ALT) - Venrock Healthcare Capital Partners III, L.P., 10%-owner of ALT bought 1.3M shares in late May then added another 1.5M shares in June with an averaged ~$8 per share. 10 days after the accumulation, ALT price jumped to $10.

Insider Smart

Celldex Therapeutics, Inc. (CLDX) - Multiple insiders including President, EVP, CEO, CSO and Directors bought shares on Jun.9th, first time since 2018, this was very convincing and we initiated a position. Stock soared from $3 to 9$ in 2 days, and the run is still going on.